Bioeq IP AG is a Swiss biopharmaceutical joint venture between the leading Polish pharmaceutical group Polpharma and the Strüngmann family’s investment company. Bioeq licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars.
FYB201 is currently the most advanced biosimilar program of Bioeq. The clinical studies and registration are conducted by a subsidiary, Bioeq GmbH based in Holzkirchen, Germany, on behalf of Bioeq IP AG.
Thomas and Andreas Strüngmann are among the most outstanding entrepreneurs in the pharmaceutical industry. In the mid-1980s they founded HEXAL AG, the largest German generic drug company, which they subsequently sold in 2005 to Novartis, along with their shares in U.S.-based Eon Labs.
Since then, Thomas and Andreas Strüngmann have been engaged in considerable investments in the German biotechnology innovation sector as well as the generics industry.
Polpharma Group is a fully integrated biopharmaceutical and generics powerhouse with more than 80 years of experience in generics development, manufacturing and commercialization. With its associated companies, it operates seven R&D and production sites and employs approximately 7,500 people providing about 700 products to patients across Poland, CEE and CIS.
Polpharma Group has established a leading role in the biosimilars industry, building on state-of-the-art development and manufacturing capabilities and strong, reliable partnerships. Polpharma Biologics runs and expands its fully integrated, biopharmaceutical development and manufacturing site network covering all required activities from cell line generation, process and product development to biopharmaceutical GMP manufacturing at up to 2000L and 500L scale in mammalian and microbial systems, respectively.
Bioeq IP AG
Phone: +41 44 533 41 00